公开(公告)号：US08431611B2

公开(公告)日：2013-04-30

申请号：US12445499

申请日：2007-10-19

申请人： Lorraine V. Brando ,  Gary H. Posner ,  John G. D'Angelo ,  Robert H. Yolken ,  Christopher P. Hencken ,  Lauren Woodard

发明人： Lorraine V. Brando ,  Gary H. Posner ,  John G. D'Angelo ,  Robert H. Yolken ,  Christopher P. Hencken ,  Lauren Woodard

IPC分类号： A01N43/02 ,  A61K31/335

CPC分类号： C07D493/18 ,  Y02A50/488

摘要： This disclosure provides improved derivatives of artemisinin; pharmaceutical compositions containing these compounds; methods for preparing these compounds and compositions; methods of using these compounds and compositions for preventing, controlling or treating infectious diseases including but not limited to parasitic infectious diseases such as T. gondii infection, trypanosome parasite infection, plasmodia parasite infection, and cryptosporidium parasite infection; methods for preventing, controlling or treating toxoplasma infection; and methods for treating psychiatric disorders associated with toxoplasma infection including but not limited to schizophrenia using the disclosed compounds and compositions alone or in combination with one or more antipsychotic drugs.

摘要翻译： 本公开提供了改善的青蒿素衍生物; 含有这些化合物的药物组合物; 制备这些化合物和组合物的方法; 使用这些化合物和组合物用于预防，控制或治疗感染性疾病的方法，包括但不限于寄生传染病如弓形虫感染，锥虫寄生虫感染，疟原虫寄生虫感染和隐孢子虫寄生虫感染; 预防，控制或治疗弓形体感染的方法; 以及使用所公开的化合物和单独的组合物或与一种或多种抗精神病药物组合来治疗与弓形体感染相关的精神疾病的方法，包括但不限于精神分裂症。

公开(公告)号：US20100093651A1

公开(公告)日：2010-04-15

申请号：US12445499

申请日：2007-10-19

申请人： Lorraine V. Brando ,  Gary H. Posner ,  John G. D'Angelo ,  Robert H. Yolken ,  Christopher P. Hencken ,  Lauren Woodard

发明人： Lorraine V. Brando ,  Gary H. Posner ,  John G. D'Angelo ,  Robert H. Yolken ,  Christopher P. Hencken ,  Lauren Woodard

IPC分类号： A61K31/366 ,  C07D407/14 ,  C07D417/14 ,  C07D493/18 ,  A61K31/427 ,  A61K31/428 ,  A61K31/4433 ,  A61K31/7048 ,  A61K31/585 ,  A61P31/00 ,  A61P25/18

CPC分类号： C07D493/18 ,  Y02A50/488

摘要： This disclosure provides improved derivatives of artemisinin; pharamaceutical compositions containing these compounds; methods for preparing these compounds and compositions; methods of using these compounds and compositions for preventing, controlling or treating infectious diseases including but not limited to parasitic infectious diseases such as T. gondii infection, trypanosome parasite infection, plasmodia parasite infection, and cryptosporidium parasite infection; methods for preventing, controlling or treating toxoplasma infection; and methods for treating psychiatric disorders associated with toxoplasma infection including but not limited to schizophrenia using the disclosed compounds and compositions alone or in combination with one or more antipsychotic drugs.

摘要翻译： 本公开提供了改善的青蒿素衍生物; 含有这些化合物的药用组合物; 制备这些化合物和组合物的方法; 使用这些化合物和组合物用于预防，控制或治疗感染性疾病的方法，包括但不限于寄生传染病如弓形虫感染，锥虫寄生虫感染，疟原虫寄生虫感染和隐孢子虫寄生虫感染; 预防，控制或治疗弓形体感染的方法; 以及使用所公开的化合物和单独的组合物或与一种或多种抗精神病药物组合来治疗与弓形体感染相关的精神疾病的方法，包括但不限于精神分裂症。

公开(公告)号：US20220356204A1

公开(公告)日：2022-11-10

申请号：US16624896

申请日：2018-06-21

申请人： David Charles Donnell BUTLER ,  Christopher P. HENCKEN ,  Nao-ki IWAMOTO ,  Pachamuthu KANDASAMY ,  Alvaro Andres LANAO ,  Genliang LU ,  Mamoru SHIMIZU ,  Sethumadhavan DIVAKARAMENON ,  Chandra VARGEESE ,  Gopal Reddy BOMMINENI ,  Subramanian MARAPPAN ,  WAVE LIFE SCIENCES LTD.

发明人： David Charles Donnell Butler ,  Christopher P. Hencken ,  Naoki Iwamoto ,  Pachamuthu Kandasamy ,  Alvaro Andres Lanao ,  Genliang Lu ,  Mamoru Shimizu ,  Sethumadhavan Divakaramenon ,  Chandra Vargeese ,  Gopal Reddy Bommineni ,  Subramanian Marappan

IPC分类号： C07H21/04 ,  C07F7/08 ,  C07D207/08 ,  C07H19/06 ,  C07C215/20 ,  C07C213/00 ,  C07D211/22 ,  C07C215/44

摘要： The present disclosure, among other things, provides technologies for synthesis, including reagents and methods for stereoselective synthesis. In some embodiments, the present disclosure provides compounds useful as chiral auxiliaries. In some embodiments, the present disclosure provides reagents and methods for oligonucleotide synthesis. In some embodiments, the present disclosure provides reagents and methods for chirally controlled preparation of oligonucleotides. In some embodiments, technologies of the present disclosure are particularly useful for constructing challenging internucleotidic linkages, providing high yields and stereoselectivity.